This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Acceleron Pharma, Inc.
Drug Names(s): ACE-083
Description: ACE-083 is a protein that acts as a modified cysteine-knot ligand trap for members in the Transforming Growth Factor-Beta (TGF-ß) superfamily. Certain proteins in the TGF-ß protein superfamily, such as myostatin and activins, normally function to modulate muscle growth. By blocking their signaling, the aim of ACE-083 is to increase muscle mass and strength. The company reports that ACE-083 has been engineered to exert this action only within the muscle or muscle group treated. They have presented preclinical data showing ACE-083 has a selective and dose-dependent increases in muscle mass in treated muscles without significant effects in untreated muscles.
Additional information available to subscribers only: